ANEBULO PHARMACEUTICALS, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
ANEBULO PHARMACEUTICALS, INC. (ANEB) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 5.48 million shares for the 6-month period ending 2025-12-31, per its 10-Q filed 2026-02-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-02-12
- ANEBULO PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-09-30 was 5.48M shares, a 19.62% increase year-over-year.
- ANEBULO PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-09-30 was 4.58M shares, a 6.12% increase year-over-year.
- ANEBULO PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-09-30 was 4.32M shares, a 3.83% increase year-over-year.
- ANEBULO PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2022-09-30 was 4.16M shares, a 588.34% increase year-over-year.
- ANEBULO PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 5.48M shares, a 19.62% increase from fiscal 2024.
- ANEBULO PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 4.58M shares, a 6.25% increase from fiscal 2023.
- ANEBULO PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 4.31M shares, a 125.69% increase from fiscal 2022.
- ANEBULO PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 1.91M shares, a 216.26% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 2 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | 5.48M shares 10-Q · filed 2026-02-12 | ||||
| 2025-09-30 | 5.48M shares 10-Q · filed 2025-11-13 | ||||
| 2025-06-30 | 5.48M shares 10-K · filed 2025-09-29 | ||||
| 2025-03-31 | 4.84M shares 10-Q · filed 2025-05-13 | ||||
| 2024-12-31 | 4.84M shares 10-Q · filed 2026-02-12 | ||||
| 2024-09-30 | 4.58M shares 10-Q · filed 2025-11-13 | ||||
| 2024-06-30 | 4.58M shares 10-K · filed 2025-09-29 | ||||
| 2024-03-31 | 4.27M shares 10-Q · filed 2025-05-13 | ||||
| 2023-12-31 | 4.64M shares 10-Q · filed 2025-02-14 | ||||
| 2023-09-30 | 4.32M shares 10-Q · filed 2024-11-13 | ||||
| 2023-06-30 | 4.31M shares 10-K · filed 2024-09-25 | ||||
| 2023-03-31 | 4.31M shares 10-Q · filed 2024-05-15 | ||||
| 2022-12-31 | 4.32M shares 10-Q · filed 2024-02-13 | ||||
| 2022-09-30 | 4.16M shares 10-Q · filed 2023-11-14 | ||||
| 2022-06-30 | 1.91M shares 10-K · filed 2023-09-22 | ||||
| 2022-03-31 | 1.48M shares 10-Q · filed 2023-05-11 | ||||
| 2021-12-31 | 661.06K shares 10-Q · filed 2023-02-10 | ||||
| 2021-09-30 | 604.40K shares 10-Q · filed 2022-11-10 | ||||
| 2021-06-30 | 604.40K shares 10-K · filed 2022-09-09 | ||||
| 2021-03-31 | 2.65M shares 10-Q · filed 2022-05-11 | ||||
| 2020-12-31 | 2.05M shares 10-Q · filed 2022-02-11 | ||||
| 2020-09-30 | 2.05M shares 10-Q · filed 2021-11-12 | ||||
| 2020-06-30 | 2.05M shares 10-K · filed 2021-09-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |